Published October 14, 2011 | Version v1
Journal article

Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration

  • 1. Charite Campus Mitte, Medizinische Klinik mit Schwerpunkt Onkologie und Haematologie, Humboldt Universitaet zu Berlin (Germany)

Description

Highlights: → CDCP1 downregulation reduces anchorage free survival of breast cancer cells. → Anoikis of CDCP1-positive breast cancer cells is increased after CDCP1 downregulation. → CDCP1 knockdown decreases migration and extensively reduces invasiveness in vitro. → Proliferation rate does not correlate with CDCP1 expression. → Lapatinib does not influence tyrosine kinases of CDCP1 signal transduction. -- Abstract: The surface receptor CUB domain-containing protein 1 (CDCP1) is highly expressed in several adenocarcinomas and speculated to participate in anchorage-independent cell survival and cell motility. Tyrosine kinase phosphorylation seems to be crucial for intracellular signaling of CDCP1. Lapatinib, a tyrosine kinase inhibitor (TKI), is approved for treatment of HER-2/neu overexpressing metastatic breast cancer and functions by preventing autophosphorylation following HER-2/neu receptor activation. This study aimed to investigate the effect of CDCP1 expression on anchorage-independent growth and cell motility of breast cancer cells. Moreover, studies were performed to examine if lapatinib provided any beneficial effect on HER-2/neu(+)/-/CDCP1+ breast cancer cell lines. In our studies, we affirmed that CDCP1 prevents cells from undergoing apoptosis when cultured in the absence of cell-substratum anchorage and that migratory and invasive properties of these cells were decreased when CDCP1 was down-regulated. However, only HER-2/neu+, but not HER-2/neu(+)/- cells showed decreased proliferation and invasion and an enhanced level of apoptosis towards loss of anchorage when treated with lapatinib. Therefore, we conclude that CDCP1 might be involved in regulating adhesion and motility of breast cancer cells but that lapatinib has no effect on tyrosine kinases regulating CDCP1. Nonetheless, other TKIs might offer therapeutic approaches for CDCP1-targeted breast cancer therapy and should be studied considering this aspect.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.bbrc.2011.09.062

Additional details

Identifiers

DOI
10.1016/j.bbrc.2011.09.062;
PII
S0006-291X(11)01653-6;

Publishing Information

Journal Title
Biochemical and Biophysical Research Communications
Journal Volume
414
Journal Issue
1
Journal Page Range
p. 226-232
ISSN
0006-291X
CODEN
BBRCA9

Optional Information

Copyright
Copyright (c) 2011 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.